<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2024//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_240101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Automated"><PMID Version="1">38828830</PMID><DateCompleted><Year>2024</Year><Month>08</Month><Day>21</Day></DateCompleted><DateRevised><Year>2024</Year><Month>08</Month><Day>21</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1520-6777</ISSN><JournalIssue CitedMedium="Internet"><Volume>43</Volume><Issue>7</Issue><PubDate><Year>2024</Year><Month>Sep</Month></PubDate></JournalIssue><Title>Neurourology and urodynamics</Title><ISOAbbreviation>Neurourol Urodyn</ISOAbbreviation></Journal><ArticleTitle>Prospective follow-up of overactive bladder symptoms in patients with prior SARS-CoV-2 infection.</ArticleTitle><Pagination><StartPage>1514</StartPage><EndPage>1522</EndPage><MedlinePgn>1514-1522</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1002/nau.25509</ELocationID><Abstract><AbstractText Label="PURPOSE" NlmCategory="OBJECTIVE">SARS-CoV-2 infection can result in genitourinary symptoms, such as frequency, urgency, nocturia, and pain/pressure. In this study, we followed the progression of overactive bladder (OAB) symptoms in patients that reported new or worsening OAB symptoms after coronavirus disease-19 (COVID-19) diagnosis.</AbstractText><AbstractText Label="MATERIALS AND METHODS" NlmCategory="METHODS">Individuals from a COVID-19 serology study were invited to participate in a follow-up study. Respondents were divided into three groups based on prior COVID-19 testing. Patients scored symptoms retrospectively before the pandemic, at study onset, and prospectively during 12-month follow-up. Genitourinary symptoms were assessed using international consultation on incontinence questionaire for OAB (ICIQ-OAB). Change in ICIQ-OAB scores from baseline were calculated. The minimal important difference of one on ICIQ-OAB is considered a significant change.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">26.0% of participants previously had positive COVID polymerase chain reaction (PCR) test (PCR+), 5.6% a positive serology test only (Ser+), and 65.5% were COVID na&#xef;ve (COVID-). 23.8% of participants reported a significant increase in ICIQ-OAB score at study onset compared to prepandemic. ICIQ-OAB scores were similar at prepandemic but significantly higher at study start (p&#x2009;&lt;&#x2009;0.001) in PCR+ group. During follow-up, change in ICIQ-OAB scores from baseline remained unchanged for COVID- group, but gradually reduced for PCR+, reaching similar levels as COVID- group by 12 months. By 12 months, 71.4% of PCR+, 42.9% of Ser+, and 68.8% of COVID- participants still reported significant increase in ICIQ-OAB scores.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Most COVID-19 patients experienced return of symptoms to baseline, indicative of the potential resolution of COVID-associated cystitis. A subset of cases did not, raising questions about the underlying factors contributing to this outcome. Additional research is needed to assess long COVID on urological health.</AbstractText><CopyrightInformation>&#xa9; 2024 Wiley Periodicals LLC.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Padmanabhan</LastName><ForeName>Priya</ForeName><Initials>P</Initials><Identifier Source="ORCID">0009-0003-7550-6305</Identifier><AffiliationInfo><Affiliation>Department of Urology, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Roberts</LastName><ForeName>Ly Hoang</ForeName><Initials>LH</Initials><Identifier Source="ORCID">0000-0002-3624-2592</Identifier><AffiliationInfo><Affiliation>Department of Urology, Glickman Urological and Kidney Institute, Cleveland Clinic, Cleveland, Ohio, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chancellor</LastName><ForeName>Michael B</ForeName><Initials>MB</Initials><Identifier Source="ORCID">0000-0001-9480-8972</Identifier><AffiliationInfo><Affiliation>Department of Urology, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peters</LastName><ForeName>Kenneth M</ForeName><Initials>KM</Initials><Identifier Source="ORCID">0000-0001-9020-598X</Identifier><AffiliationInfo><Affiliation>Department of Urology, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Zwaans</LastName><ForeName>Bernadette M M</ForeName><Initials>BMM</Initials><Identifier Source="ORCID">0000-0002-4717-5751</Identifier><AffiliationInfo><Affiliation>Department of Urology, Corewell Health William Beaumont University Hospital, Royal Oak, Michigan, USA.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Department of Urology, Oakland University William Beaumont School of Medicine, Rochester, Michigan, USA.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>06</Month><Day>03</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurourol Urodyn</MedlineTA><NlmUniqueID>8303326</NlmUniqueID><ISSNLinking>0733-2467</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000150" MajorTopicYN="N">complications</QualifierName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D053201" MajorTopicYN="Y">Urinary Bladder, Overactive</DescriptorName><QualifierName UI="Q000175" MajorTopicYN="N">diagnosis</QualifierName><QualifierName UI="Q000503" MajorTopicYN="N">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D011446" MajorTopicYN="N">Prospective Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005500" MajorTopicYN="N">Follow-Up Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="N">Disease Progression</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID&#x2010;19</Keyword><Keyword MajorTopicYN="N">SARS&#x2010;CoV&#x2010;2</Keyword><Keyword MajorTopicYN="N">cystitis</Keyword><Keyword MajorTopicYN="N">overactive bladder</Keyword><Keyword MajorTopicYN="N">urinary bladder</Keyword><Keyword MajorTopicYN="N">urinary incontinence</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>3</Month><Day>21</Day></PubMedPubDate><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>2</Month><Day>8</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>5</Month><Day>20</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>21</Day><Hour>17</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>12</Hour><Minute>45</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>6</Month><Day>3</Day><Hour>6</Hour><Minute>43</Minute></PubMedPubDate></History><PublicationStatus>ppublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">38828830</ArticleId><ArticleId IdType="doi">10.1002/nau.25509</ArticleId></ArticleIdList><ReferenceList><Title>REFERENCES</Title><Reference><Citation>Cherry JD, Krogstad P. SARS: the first pandemic of the 21st century. Pediatr Res. 2004;56(1):1&#x2010;5. doi:10.1203/01.PDR.0000129184.87042.FC</Citation></Reference><Reference><Citation>Rabi FA, Al Zoubi MS, Kasasbeh GA, Salameh DM, Al&#x2010;Nasser AD. SARS&#x2010;CoV&#x2010;2 and coronavirus disease 2019: what we know so far. Pathogens. 2020;9(3):231. doi:10.3390/pathogens9030231</Citation></Reference><Reference><Citation>World Health Organization. WHO coronavirus (COVID19) dashboard. 2023. Accessed July 1, 2023. https://covid19.who.int/</Citation></Reference><Reference><Citation>da Rosa Mesquita R, Francelino Silva Junior LC, Santos Santana FM, et al. Clinical manifestations of COVID&#x2010;19 in the general population: systematic review. Wien Klin Wochenschr. 2021;133(7&#x2010;8):377&#x2010;382. doi:10.1007/s00508-020-01760-4</Citation></Reference><Reference><Citation>Carod&#x2010;Artal FJ. Post&#x2010;COVID&#x2010;19 syndrome: epidemiology, diagnostic criteria and pathogenic mechanisms involved. Rev Neurol. 2021;72(11):384&#x2010;396. doi:10.33588/rn.7211.2021230</Citation></Reference><Reference><Citation>Ahmad SJ, Feigen CM, Vazquez JP, Kobets AJ, Altschul DJ. Neurological sequelae of COVID&#x2010;19. J Integr Neurosci. 2022;21(3):77. doi:10.31083/j.jin2103077</Citation></Reference><Reference><Citation>Roy D, Ghosh R, Dubey S, Dubey MJ, Benito&#x2010;Le&#xf3;n J, Kanti Ray B. Neurological and neuropsychiatric impacts of COVID&#x2010;19 pandemic. Can J Neurol Sci. 2021;48(1):9&#x2010;24. doi:10.1017/cjn.2020.173</Citation></Reference><Reference><Citation>van Kessel SAM, Olde Hartman TC, Lucassen PLBJ, van Jaarsveld CHM. Post&#x2010;acute and long&#x2010;COVID&#x2010;19 symptoms in patients with mild diseases: a systematic review. Fam Pract. 2022;39(1):159&#x2010;167. doi:10.1093/fampra/cmab076</Citation></Reference><Reference><Citation>LaVergne SM, Stromberg S, Baxter BA, et al. A longitudinal SARS&#x2010;CoV&#x2010;2 biorepository for COVID&#x2010;19 survivors with and without post&#x2010;acute sequelae. BMC Infect Dis. 2021;21(1):677. doi:10.1186/s12879-021-06359-2</Citation></Reference><Reference><Citation>Hoang Roberts L, Zwaans BMM, Peters KM, Chancellor M, Padmanabhan P. Incidence of new or worsening overactive bladder among patients with a prior SARS&#x2010;CoV&#x2010;2 infection: a cohort study. Eur Urol Open Sci. 2022;46:68&#x2010;74. doi:10.1016/j.euros.2022.10.001</Citation></Reference><Reference><Citation>Lamb LE, Timar R, Wills M, et al. Long COVID and COVID&#x2010;19&#x2010;associated cystitis (CAC). Int Urol Nephrol. 2022;54(1):17&#x2010;21. doi:10.1007/s11255-021-03030-2</Citation></Reference><Reference><Citation>Breyer BN, Van den Eeden SK, Horberg MA, et al. HIV status is an independent risk factor for reporting lower urinary tract symptoms. J Urol. 2011;185(5):1710&#x2010;1715. doi:10.1016/j.juro.2010.12.043</Citation></Reference><Reference><Citation>Castro NM, Rodrigues Jr. W, Freitas DM, Muniz A, Oliveira P, Carvalho EM. Urinary symptoms associated with human T&#x2010;cell lymphotropic virus type I infection: evidence of urinary manifestations in large group of HTLV&#x2010;I carriers. Urology. 2007;69(5):813&#x2010;818. doi:10.1016/j.urology.2007.01.052</Citation></Reference><Reference><Citation>Jhang JF, Hsu YH, Peng CW, Jiang YH, Ho HC, Kuo HC. Epstein&#x2010;Barr virus as a potential etiology of persistent bladder inflammation in human interstitial cystitis/bladder pain syndrome. J Urol. 2018;200(3):590&#x2010;596. doi:10.1016/j.juro.2018.03.133</Citation></Reference><Reference><Citation>Mufson MA, Belshe RB. A review of adenoviruses in the etiology of acute hemorrhagic cystitis. J Urol. 1976;115(2):191&#x2010;194. doi:10.1016/s0022-5347(17)59130-2</Citation></Reference><Reference><Citation>Pinto M, Dobson S. BK and JC virus: a review. J Infect. 2014;68(suppl 1):S2&#x2010;S8. doi:10.1016/j.jinf.2013.09.009</Citation></Reference><Reference><Citation>Winter BJ, O'Connell HE, Bowden S, Carey M, Eisen DP. A case control study reveals that polyomaviruria is significantly associated with interstitial cystitis and vesical ulceration. PLoS One. 2015;10(9):e0137310. doi:10.1371/journal.pone.0137310</Citation></Reference><Reference><Citation>Lamb LE, Dhar N, Timar R, Wills M, Dhar S, Chancellor MB. COVID&#x2010;19 inflammation results in urine cytokine elevation and causes COVID&#x2010;19 associated cystitis (CAC). Med Hypotheses. 2020;145:110375. doi:10.1016/j.mehy.2020.110375</Citation></Reference><Reference><Citation>Sims MD, Maine GN, Childers KL, et al. Coronavirus disease 2019 (COVID&#x2010;19) seropositivity and asymptomatic rates in healthcare workers are associated with job function and masking. Clin Infect Dis. 2021;73(suppl 2):S154&#x2010;S162. doi:10.1093/cid/ciaa1684</Citation></Reference><Reference><Citation>Sari Motlagh R, Hajebrahimi S, Sadeghi&#x2010;Bazargani H, Joodi Tutunsaz J. Reliability and validation of the international consultation on incontinence questionnaire in over active bladder to Persian language. Low Urin Tract Symptoms. 2015;7(2):99&#x2010;101. doi:10.1111/luts.12059</Citation></Reference><Reference><Citation>Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Controlled Clin Trials. Dec 1989;10(4):407&#x2010;415. doi:10.1016/0197-2456(89)90005-6</Citation></Reference><Reference><Citation>Mumm JN, Osterman A, Ruzicka M, et al. Urinary frequency as a possibly overlooked symptom in COVID&#x2010;19 patients: does SARS&#x2010;CoV&#x2010;2 cause viral cystitis. Eur Urol. 2020;78(4):624&#x2010;628. doi:10.1016/j.eururo.2020.05.013</Citation></Reference><Reference><Citation>Ceban F, Ling S, Lui LMW, et al. Fatigue and cognitive impairment in post&#x2010;COVID&#x2010;19 syndrome: a systematic review and meta&#x2010;analysis. Brain Behav Immun. 2022;101:93&#x2010;135. doi:10.1016/j.bbi.2021.12.020</Citation></Reference><Reference><Citation>Davis HE, McCorkell L, Vogel JM, Topol EJ. Long COVID: major findings, mechanisms and recommendations. Nat Rev Microbiol. 2023;21(3):133&#x2010;146. doi:10.1038/s41579-022-00846-2</Citation></Reference><Reference><Citation>Pellegrini D, Kawakami R, Guagliumi G, et al. Microthrombi as a major cause of cardiac injury in COVID&#x2010;19: a pathologic study. Circulation. 2021;143(10):1031&#x2010;1042. doi:10.1161/CIRCULATIONAHA.120.051828</Citation></Reference><Reference><Citation>Peiris S, Mesa H, Aysola A, et al. Pathological findings in organs and tissues of patients with COVID&#x2010;19: a systematic review. PLoS One. 2021;16(4):e0250708. doi:10.1371/journal.pone.0250708</Citation></Reference><Reference><Citation>Fahmy OH, Daas FM, Salunkhe V, et al. Is microthrombosis the main pathology in coronavirus disease 2019 severity?&#x2010;a systematic review of the postmortem pathologic findings. Crit Care Explor. 2021;3(5):e0427. doi:10.1097/CCE.0000000000000427</Citation></Reference><Reference><Citation>Santomauro D.F.MD, Mantilla Herrera AM, Shadid J, et al. Global prevalence and burden of depressive and anxiety disorders in 204 countries and territories in 2020 due to the COVID&#x2010;19 pandemic. Lancet. 2021;398(10312):1700&#x2010;1712. doi:10.1016/S0140-6736(21)02143-7</Citation></Reference><Reference><Citation>Lai HH, Shen B, Rawal A, Vetter J. The relationship between depression and overactive bladder/urinary incontinence symptoms in the clinical OAB population. BMC Urol. 2016;16(1):60. doi:10.1186/s12894-016-0179-x</Citation></Reference><Reference><Citation>Sakakibara R, Ito T, Yamamoto T, et al. Depression, anxiety and the bladder. Low Urin Tract Symptoms. 2013;5(3):109&#x2010;120. doi:10.1111/luts.12018</Citation></Reference><Reference><Citation>Zhao Z, Salerno S, Shi X, Lee S, Mukherjee B, Fritsche LG. Understanding the patterns of serological testing for COVID&#x2010;19 pre&#x2010; and post&#x2010;vaccination rollout in Michigan. J Clin Med. 2021;10(19):4341. doi:10.3390/jcm10194341</Citation></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>